GlobeNewswire PharmaOriginal article
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
Data ReadoutpositivePRPPositive
AI Analysis
Summary
Propanc Biopharma announced positive preclinical and early translational data for PRP demonstrating >90% tumor growth inhibition and significant survival benefit in pancreatic ductal adenocarcinoma models through targeting cancer stem cells and disrupting the fibrotic microenvironment.
Clinical Trial Data
Phase
preclinical/early translational
Outcome Details
>90% tumor growth inhibition and significant survival benefit in pancreatic ductal adenocarcinoma models
Importance:5/10
Sentiment:
0.75
pancreatic cancerpreclinical datatumor inhibitioncancer stem cellssurvival benefit
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 6, 2026 12:30 PM